RN Mobile Menu


Rheumatology Network

Clinical Trial Results for an RA Biosimilar are Encouraging

Results are coming in from clinical trials of biosimilar drugs for rheumatoid arthritis. One new study shows comparable outcomes to an existing therapeutic, but some concerns are being raised about potential and pitfalls. (Photo credit @sfam_photo.)

Recent Content

Psoriasis and psoriatic arthritis have long been associated with cardiovascular disease and deaths, but now a large population study from Taiwan indicates the danger of cardiac arrhythmias is increased independently of traditional risk factors such as coronary disease and high blood pressure.


Little is known about the etiology of juvenile idiopathic arthritis, but now a new study shows an association between antibiotic use and newly diagnosed cases of JIA.

Intravenous Medications

Clinical trial of 120 RA patients shows that adalimumab (Exemptia) works as well as adalimumab (Humira).

The majority of pregnant patients with systemic lupus erythematosus (SLE) have favorable pregnancy outcomes, with few experiencing severe flares.


Study shows that the inflammatory process associated with systemic lupus erythematosus may contribute to MetS over time.

Patients diagnosed with systemic sclerosis (SSc) may have a three times greater risk of venous thromboembolism (VTE) – including potentially deadly clots in the lungs – and an increased risk in the first year after a diagnosis.

Plaque psoriasis. (Tanya Munger, MSN and Robert Bales, MD, MPH)

Guselkumab, a selective antagonist of IL-23, went head to head with adalimumab in a year-long phase 2 trial of 293 patients with moderate to severe plaque psoriasis. A quick synopsis of the results here.

By clicking Accept, you agree to become a member of the UBM Medica Community.